Swe Ei, Begun Jakob
Gastroenterology, Mater Hospital Brisbane, Brisbane, AUS.
Cureus. 2025 Apr 10;17(4):e82002. doi: 10.7759/cureus.82002. eCollection 2025 Apr.
Sarcoidosis is a multisystem granulomatous disorder of unclear aetiology. It can develop de novo or occur as a reaction to certain medications. While infliximab is commonly used for treating inflammatory conditions such as inflammatory bowel disease, paradoxical sarcoidosis secondary to tumor necrosis factor alpha (TNF-α) inhibitors is a rare complication. There is emerging evidence to support the use of Janus kinase (JAK) inhibitors in refractory sarcoidosis. Here, we present the first reported case of infliximab-induced pulmonary sarcoidosis in a patient with Crohn's disease successfully treated with upadacitinib and review the literature.
结节病是一种病因不明的多系统肉芽肿性疾病。它可新发，也可作为对某些药物的反应而发生。英夫利昔单抗常用于治疗炎症性疾病，如炎症性肠病，而肿瘤坏死因子α（TNF-α）抑制剂继发的矛盾性结节病是一种罕见的并发症。越来越多的证据支持在难治性结节病中使用 Janus 激酶（JAK）抑制剂。在此，我们报告首例克罗恩病患者因英夫利昔单抗诱发肺结节病并成功使用乌帕替尼治疗的病例，并对文献进行综述。
